1. Selecting and Applying Chemotherapy

3. Introduction: Discussion Topic

4. The Role of Chemotherapy in MBC

5. ABC 3 Guidelines: Factors Influencing Treatment Choice

6. Monotherapy vs Combination Chemotherapy

7. Duration of Chemotherapy

8. Optimal Duration of Chemotherapy?

9. Main Goals in the Treatment of MBC

10. International Guidelines Regarding the Role of Chemotherapy in MBC

11. Choice of First-line Chemotherapy in HER2-Negative MBC

12. Which Chemotherapy Regimen?

13. HERNATA: Vinorelbine in HER2-positive MBC

14. Phase 2 NorBreast-231 Trial: Clinical Activity in the ITT Population

15. Hematological Toxicities: Worst Grade

16. Nonhematological Toxicities: Worst Grade

17. Phase 2 NorBreast-231 Trial: OS

18. Considerations for Oral CT for MBC

19. Managing TEAEs Related to Oral Vinorelbine

20. Metronomic CT

21. Oral Vinorelbine in the First-line Setting for MBC and NSCLC: The Chinese Experience

22. Oral Vinorelbine in the First-line Setting for MBC and NSCLC: Results

23. Potential Benefit of Oral Vinorelbine in China

24. Conclusions